Comparable stake leader
ACORN BIOVENTURES, L.P.
SEC ownership of BioAtla, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001826892.
Disclosed value leader
Guy Levy
Comparable rows
47/50
Latest evidence
31 Mar 2026
- Public ticker
- BCAB on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ACORN BIOVENTURES, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
47 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ACORN BIOVENTURES, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001826892
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of BioAtla, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ACORN BIOVENTURES, L.P.
Disclosed value leader
Guy Levy
Comparable rows
47/50
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 8.3%
3 rows are not safely comparable across share classes.
13D/G row: ACORN BIOVENTURES, L.P.
Showing 1-8 of 50 holder rows.
Quick read
ACORN BIOVENTURES, L.P. leads the comparable SEC ownership view at 8.3%.
47 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ACORN BIOVENTURES, L.P.'s linked filing trail.
Comparable ownership
Top 5
ACORN BIOVENTURES, L.P.
8.3%
HIGHBRIDGE CAPITAL MANAGEMENT LLC
7.7%
Jay M. Short PhD
6.6%
OPOKA INVESTMENT FUND Co
4.8%
MILLENNIUM MANAGEMENT LLC
1.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ACORN BIOVENTURES, L.P. |
13D/G
Anders Hove
|
8.3%
|
$2,127,449
4,835,111 shares
|
$0 | 15 May 2025 |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC |
13D/G
|
7.7%
|
$2,129,415
4,839,579 shares
|
-$1,104,235 | 31 Mar 2025 |
| Jay M. Short PhD |
13D/G
3/4/5
Jay M. Short · Chief Executive Officer, Director
|
6.6%
|
$1,700,884
3,865,646 shares
|
$0 | 31 Dec 2024 |
| OPOKA INVESTMENT FUND Co |
13D/G
|
4.8%
|
$1,933,227
2,810,331 shares
|
-$507,296 | 09 Jul 2025 |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
Company
|
1.9%
|
$482,067
1,095,606 shares
|
$0 | 31 Dec 2024 |
| Richard A. Waldron |
3/4/5
Former Chief Financial Officer
|
0.59%
|
$84,824
343,421 shares
|
— | 28 Feb 2026 |
| Scott Andrew Smith |
3/4/5
Director
|
0.55%
|
$125,404
321,550 shares
|
— | 18 Jun 2025 |
| Lawrence Steinman |
3/4/5
Director
|
0.13%
|
$30,599
78,459 shares
|
— | 18 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 25 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-12 of 12 reporting-owner rows connected to BioAtla, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
12
Largest Forms 3/4/5 holder
Guy Levy
Net 12M change
$0
Latest report
12 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Guy Levy | Former Director | $2,781,493 | Mixed | 16 Jun 2022 | ||
| Scott Andrew Smith | Director | $125,404 | Mixed | 18 Jun 2025 | ||
| Richard A. Waldron | Former Chief Financial Officer | $84,824 | Mixed | 28 Feb 2026 | ||
| Lawrence Steinman | Director | $30,599 | Mixed | 18 Jun 2025 | ||
| Mary Ann Gray | Director | $30,184 | Mixed | 18 Jun 2025 | ||
| Eddie Williams | Director | $23,478 | Mixed | 18 Jun 2025 | ||
| Sylvia McBrinn | Director | $23,058 | Mixed | 18 Jun 2025 | ||
| Susan Moran | Director | $20,399 | Mixed | 18 Jun 2025 | ||
| Jay M. Short PhD | Chief Executive Officer, Director | $12,611 | Mixed | 12 Mar 2026 | ||
| Eric Sievers | Chief Medical Officer | $1,906 | Median | 11 Mar 2026 | ||
| Christian Vasquez | Chief Financial Officer | $1,665 | Median | 11 Mar 2026 | ||
| Himalaya Parent LLC | 10%+ Owner | $123 | Mixed | 14 Jun 2021 |
Recent insider transactions for BioAtla, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Christian Vasquez | BCAB | Common Stock | Tax liability | -0.79% | -82 | 10,347 | 31 May 2026 | Direct | ||
| Jay M. Short PhD | BCAB | Common Stock | Tax liability | -0.49% | -259 | 52,294 | 31 May 2026 | Direct | ||
| Eric Sievers | BCAB | Common Stock | Tax liability | -1.12% | -134 | 11,840 | 31 May 2026 | Direct | ||
| Jay M. Short PhD | BCAB | Common Stock | Tax liability | -1.2% | -639 | 52,553 | 12 Mar 2026 | Direct | ||
| Christian Vasquez | BCAB | Common Stock | Tax liability | -1.65% | -175 | 10,429 | 11 Mar 2026 | Direct | ||
| Eric Sievers | BCAB | Common Stock | Tax liability | -3.01% | -360 | 11,614 | 11 Mar 2026 | Direct | ||
| Jay M. Short PhD | BCAB | Common Stock | Award | 19.3% | 430,000 | 2,659,603 | 11 Mar 2026 | Direct | ||
| Eric Sievers | BCAB | Common Stock | Award | 66.9% | 240,000 | 598,705 | 10 Mar 2026 | Direct | ||
| Christian Vasquez | BCAB | Common Stock | Award | 82.7% | 240,000 | 530,196 | 10 Mar 2026 | Direct | ||
| Jay M. Short PhD | BCAB | Common Stock | Tax liability | -0.35% | -7,728 | 2,229,603 | 28 Feb 2026 | Direct | ||
| Christian Vasquez | BCAB | Common Stock | Tax liability | -0.62% | -1,802 | 290,196 | 28 Feb 2026 | Direct | ||
| Richard A. Waldron | BCAB | Common Stock | Tax liability | -0.79% | -2,729 | 343,421 | 28 Feb 2026 | Direct | ||
| Eric Sievers | BCAB | Common Stock | Tax liability | -0.87% | -3,140 | 358,705 | 28 Feb 2026 | Direct | ||
| Richard A. Waldron | BCAB | Common Stock | Tax liability | -0.68% | -2,371 | 346,150 | 30 Nov 2025 | Direct | ||
| Eric Sievers | BCAB | Common Stock | Tax liability | -0.75% | -2,729 | 361,845 | 30 Nov 2025 | Direct | ||
| Jay M. Short PhD | BCAB | Common Stock | Tax liability | -0.28% | -6,347 | 2,237,331 | 30 Nov 2025 | Direct | ||
| Christian Vasquez | BCAB | Common Stock | Tax liability | -0.53% | -1,566 | 291,998 | 30 Nov 2025 | Direct | ||
| Jay M. Short PhD | BCAB | Common Stock | Tax liability | -0.28% | -6,347 | 2,243,678 | 31 Aug 2025 | Direct | ||
| Christian Vasquez | BCAB | Common Stock | Tax liability | -0.55% | -1,566 | 283,564 | 31 Aug 2025 | Direct | ||
| Eric Sievers | BCAB | Common Stock | Tax liability | -0.74% | -2,729 | 364,574 | 31 Aug 2025 | Direct | ||
| Richard A. Waldron | BCAB | Common Stock | Tax liability | -0.7% | -2,371 | 338,521 | 31 Aug 2025 | Direct |
* marks a reported price that did not pass the local price check.